{"ticker": {"uuid": "c4b2160a-cb0c-412b-bfd5-45a18c968ec7", "symbol": "300122", "name": "Chongqing Zhifei Biological Products Co., Ltd.", "exchange": "SHZ", "country": "CN", "sector": "Healthcare", "industry": "Biotechnology"}, "articles": [{"title": "Chongqing Zhifei Biological Products Plans Share Buyback", "summary": "", "url": "https://news.google.com/rss/articles/CBMixAFBVV95cUxQdU9IdFdodGdfbDJSbkpYY2N1LVdkc2Q4c25mQWxHQ0djSllsOVQ5bUs0SmROVXVldnc3cWJkOGhMd05sSkc1ZkJsRkJnamZ6OUpKOHFrV2RJSWE0TzMxRzF6WTVwdWprWFljby0taUdlNVlobmJ6SmdLeU1jOEZnZlN3NmtFSUNjMjhUU2tIRnE0VU5KV2F2R1p3M3I0eE5iWlNjdVl3SVBENU1YUEhwWkpkVmdQek5vU1ZOUERRSFhCbFdq?oc=5", "source_name": "TradingView", "published_at": "2026-07-20T10:41:42+00:00", "published_display": "20 Jul 2026 10:41", "sentiment": "positive", "sentiment_pct": 62, "event_type": "capital_return", "event_label": "Capital return", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to sales forward of Chongqing Zhifei Biological Products Co., Ltd. Class A \u2013 SZSE:300122", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxQemlZM3VpSjNwQTJLeTlNb2hjUzk2TWczMkRkWTlqQng0NDM1bVpVSFJfa0s0VDByS0p3Y0RsWGNCZG1JaG5CLV9vekczT3p2eldUSklBRXdnYzh4TGNiSVZycmc4ZmJMdzdBVGE1MU13Vkh4UHdYSTlHeG9fWjRNWHNvc3JOVFVBTXBZbXJSVG1KcUFYOHRFbk10YU1Bdw?oc=5", "source_name": "TradingView", "published_at": "2026-07-07T05:08:11+00:00", "published_display": "07 Jul 2026 05:08", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "GSK cuts Shingrix deliveries in revised Zhifei China pact, moves closer to RSV vaccine deal", "summary": "", "url": "https://news.google.com/rss/articles/CBMiugFBVV95cUxPYWQySFZNMzJhYXZDUFdDQ1AwNTVtUFdyZXdqYW42WkdDaWg3Y01SVlZGUkpzZUFPM3VPbUZuX2pXTXJlYXc4bDN1ZlJUNjJFV2lVX1JWSjE0akxJcGxWRlJFUFc5c0tsTDcwenlUUm0xSXhvV0Zza20xTXV0RHJVd3RodmowbDIyTFdVNmI1M0Uxd0RXNk41RXl5d1MtTklZcHpBRDVtWVIwUG1URVowbTE2MFBoR24wX2c?oc=5", "source_name": "Fierce Pharma", "published_at": "2024-12-05T08:00:00+00:00", "published_display": "05 Dec 2024 08:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "GSK signs shingles vaccine deal with China's Zhifei for around $3 bln", "summary": "", "url": "https://news.google.com/rss/articles/CBMizwFBVV95cUxPS1hnemlrTzFTcmVudEtyekhMZGE1Nm5XV2RMZ0NMQUhWMFRYYl9RX2h5eEkyWFlfSzNmcE5EalJGU0x1bTdLUEZfUEtXVW5YN3JWOU51WWZVaVoyZUVVQndEaGtCYk4xTGI3SW0zcDVibHRENXh4R2hFSGloeGhPOXlQQW1PanhWSGhOZEs4U2VnSjRfMHNWbFk0U3pzb0ljRDJrR09NMndnYk5FNV9WazJLQjNQQU1aOHo2VFpnQkU5Q0VnZ1kzZzZLcU55elU?oc=5", "source_name": "Reuters", "published_at": "2023-10-09T07:00:00+00:00", "published_display": "09 Oct 2023 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}], "by_tier": {"direct": [{"title": "Chongqing Zhifei Biological Products Plans Share Buyback", "summary": "", "url": "https://news.google.com/rss/articles/CBMixAFBVV95cUxQdU9IdFdodGdfbDJSbkpYY2N1LVdkc2Q4c25mQWxHQ0djSllsOVQ5bUs0SmROVXVldnc3cWJkOGhMd05sSkc1ZkJsRkJnamZ6OUpKOHFrV2RJSWE0TzMxRzF6WTVwdWprWFljby0taUdlNVlobmJ6SmdLeU1jOEZnZlN3NmtFSUNjMjhUU2tIRnE0VU5KV2F2R1p3M3I0eE5iWlNjdVl3SVBENU1YUEhwWkpkVmdQek5vU1ZOUERRSFhCbFdq?oc=5", "source_name": "TradingView", "published_at": "2026-07-20T10:41:42+00:00", "published_display": "20 Jul 2026 10:41", "sentiment": "positive", "sentiment_pct": 62, "event_type": "capital_return", "event_label": "Capital return", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to sales forward of Chongqing Zhifei Biological Products Co., Ltd. Class A \u2013 SZSE:300122", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxQemlZM3VpSjNwQTJLeTlNb2hjUzk2TWczMkRkWTlqQng0NDM1bVpVSFJfa0s0VDByS0p3Y0RsWGNCZG1JaG5CLV9vekczT3p2eldUSklBRXdnYzh4TGNiSVZycmc4ZmJMdzdBVGE1MU13Vkh4UHdYSTlHeG9fWjRNWHNvc3JOVFVBTXBZbXJSVG1KcUFYOHRFbk10YU1Bdw?oc=5", "source_name": "TradingView", "published_at": "2026-07-07T05:08:11+00:00", "published_display": "07 Jul 2026 05:08", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "GSK cuts Shingrix deliveries in revised Zhifei China pact, moves closer to RSV vaccine deal", "summary": "", "url": "https://news.google.com/rss/articles/CBMiugFBVV95cUxPYWQySFZNMzJhYXZDUFdDQ1AwNTVtUFdyZXdqYW42WkdDaWg3Y01SVlZGUkpzZUFPM3VPbUZuX2pXTXJlYXc4bDN1ZlJUNjJFV2lVX1JWSjE0akxJcGxWRlJFUFc5c0tsTDcwenlUUm0xSXhvV0Zza20xTXV0RHJVd3RodmowbDIyTFdVNmI1M0Uxd0RXNk41RXl5d1MtTklZcHpBRDVtWVIwUG1URVowbTE2MFBoR24wX2c?oc=5", "source_name": "Fierce Pharma", "published_at": "2024-12-05T08:00:00+00:00", "published_display": "05 Dec 2024 08:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "GSK signs shingles vaccine deal with China's Zhifei for around $3 bln", "summary": "", "url": "https://news.google.com/rss/articles/CBMizwFBVV95cUxPS1hnemlrTzFTcmVudEtyekhMZGE1Nm5XV2RMZ0NMQUhWMFRYYl9RX2h5eEkyWFlfSzNmcE5EalJGU0x1bTdLUEZfUEtXVW5YN3JWOU51WWZVaVoyZUVVQndEaGtCYk4xTGI3SW0zcDVibHRENXh4R2hFSGloeGhPOXlQQW1PanhWSGhOZEs4U2VnSjRfMHNWbFk0U3pzb0ljRDJrR09NMndnYk5FNV9WazJLQjNQQU1aOHo2VFpnQkU5Q0VnZ1kzZzZLcU55elU?oc=5", "source_name": "Reuters", "published_at": "2023-10-09T07:00:00+00:00", "published_display": "09 Oct 2023 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}], "industry": [], "sector": []}, "total_fetched": 67, "total_relevant": 4, "sentiment_summary": {"positive": 1, "negative": 1, "neutral": 2, "score": 52, "total": 4, "label": "Balanced news tone", "tone": "neutral"}, "classifier": {"primary_event": "deals", "primary_label": "Deals and strategy", "confidence": 65, "events": [{"event": "deals", "label": "Deals and strategy", "weight": 1.45, "count": 2}, {"event": "capital_return", "label": "Capital return", "weight": 0.55, "count": 1}, {"event": "general", "label": "Market update", "weight": 0.55, "count": 1}], "positive_events": 1, "negative_events": 1}, "market_context": {"has_market_context": true, "latest_close": 12.27, "latest_week": "2026-07-17", "one_week_move": 0.8, "four_week_move": 0.5, "twelve_week_move": -17.1, "trend_signal": "0", "trend_label": "Trend inactive", "trend_tone": "negative", "market_dynamics": -0.785998, "market_dynamics_buy_signal": false, "relative_strength": -33.43659, "fair_value_gap": -58.1, "fair_value_label": "Below fair value", "fair_value_tone": "positive", "expectation_direction": "negative", "expectation_probability": 42.1982, "reaction_label": "Price digesting", "reaction_tone": "neutral", "market_sentence": "+0.8% over one week, +0.5% over four weeks, trend inactive, and below fair value."}, "interpretation": {"label": "Balanced read", "tone": "neutral", "classification": "balanced", "summary": "News tone and price action are not far from neutral.", "confidence": 45, "badges": ["Value support"], "opportunities": ["Price is below fair value while news tone is not negative."], "risks": [], "event_label": "Deals and strategy", "sentiment_word": "balanced"}, "charts": {"sources": [{"label": "TradingView", "count": 2}, {"label": "Fierce Pharma", "count": 1}, {"label": "Reuters", "count": 1}], "tiers": [{"label": "Direct company coverage", "count": 4}, {"label": "Industry context", "count": 0}, {"label": "Sector context", "count": 0}], "events": [{"label": "Deals and strategy", "count": 2}, {"label": "Capital return", "count": 1}, {"label": "Market update", "count": 1}]}, "insights": [{"label": "Weighted tone", "value": "52/100", "tone": "neutral", "text": "Balanced news tone"}, {"label": "Market reaction", "value": "Balanced read", "tone": "neutral", "text": "News tone and price action are not far from neutral."}, {"label": "Primary event", "value": "Deals and strategy", "tone": "neutral", "text": "65/100 classification confidence."}, {"label": "Company focus", "value": "4", "tone": "positive", "text": "directly relevant articles"}, {"label": "Source quality", "value": "1", "tone": "positive", "text": "high-authority source matches"}, {"label": "Trend context", "value": "Trend inactive", "tone": "negative", "text": "+0.8% over one week, +0.5% over four weeks, trend inactive, and below fair value."}, {"label": "Latest direct headline", "value": "Positive", "tone": "positive", "text": "Chongqing Zhifei Biological Products Plans Share Buyback"}], "updated_at": "2026-07-22T00:59:11.646927+00:00", "disclaimer": "Educational market research only. Not financial, investment, trading, tax, or legal advice."}